Earlier Monday, the U.S. FDA approved Bausch + Lomb's (BlCO) eye surgery product, the Teneo Excimer Laser Platform, to conduct a surgical procedure called keratomileusis (LASIK).

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...

Bausch + Lomb said it authorized management and advisers to explore a potential sale of the eye health company after shares dropped over reports of faltering deal talks with a group of private ...

Bausch + Lomb Corp (NYSE:BLCO; TSX:BLCO), a global leader in eye health products, has recently experienced a mix of positive developments and challenges that have caught the attention of investors ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global leader in eye health products with a market capitalization of $6.55 billion, has been navigating a complex market landscape in 2024.